Part 3: Managing testing efficiencies – How to optimise next generation sequencing and HRR testing
Prof Jack Cuzick talks to ecancer at the 2013 European Cancer Congress in Amsterdam about the role of prostate cancer screening and why two trials, European Randomized Study of Screening for Prostate Cancer (ERSPC) and the PLCO trial, came to different conclusions about its benefits.
Part 3: Managing testing efficiencies – How to optimise next generation sequencing and HRR testing
Powering equity in cancer care through digital health
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Psychological issues in familial cancer
Best practice in HRRm testing in patients with metastatic prostate cancer
Genomic testing: Awareness and effective communication between healthcare professionals and patients
The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer
iCCaRE Consortium for Black Men: Second Discussion